MainNews -

Scoop of the day: CoronaVac completes clinical trials with 83.5% efficacy

Scoop of the day: CoronaVac completes clinical trials with 83.5% efficacy


The Lekkhim pharmaceutical group, an authorised Ukrainian representative of Sinovac Tech, has said that the CoronaVac has successfully undergone phase 3 of clinical trials in Turkey, having shown the 83.5% efficacy.

Sinovac is expected to arrive in Ukraine by 15 March.

On the morning of 4 March, Ukraine has reported 10,057 new Covid-19 cases after running 83,086 tests. The daily increment has exceeded 10,000 for the first time since December.

Two cases of the British variant of Covid-19 have been officially confirmed in Ukraine, Segodnya has said, quoting the Institute of Epidemiology and Infectious Diseases. The patients are under medical observation.

Dual citizenship

President Volodymyr Zelenskyy has enacted the National Security and Defence Council's decree seeking to clarify dual citizenship status in Ukraine and ultimately ban individuals holding or apply for foreign citizenship from holding government posts in Ukraine.


The state defence company Ukrspetseksport has denied media reports that the Defence Ministry bought surplus Soviet ammunition. The company said that 100-mm artillery rounds were bought from a Czech supplier and they have been refilled and reassembled in recent years.

Parliament has refused to pass bills on the legalization of guns.


Slovak Prime Minister Igor Matovič's has apologized for his joke that he had promised Russia "Ukraine's Transcarpathian Region" in exchange for its Sputnik V vaccine supply. "Slovakia is your friend," he tweeted.


Chinese investors of the Ukrainian engine maker Motor Sich have not delivered on the terms of the investment programme, the company's president Vyacheslav Bohuslayev has said at a meeting of the parliamentary committee on national security, defence and intelligence. "There is no investment agreement on the part of Chinese comrades. They have fooled us," he said.

Read news on social networks Facebook, Twitter and Telegram